Successful Direct Offerings
The company closed a $2.5 million registered direct offering in January and a $1.1 million registered direct offering in March, providing crucial funds for operations.
Positive Regulatory Guidance
Received positive regulatory guidance from the European Medicines Agency for the ibezapolstat Phase 3 clinical trial program, aligning with the FDA on key aspects.
Scientific Advancements
New publications in the Journal of Antimicrobial Agents and Chemotherapeutics highlighted the microbiome restorative potential of ibezapolstat and its selective antibacterial activity.
Patent Milestones
Secured new patents in Japan and India for DNA pol IIIC inhibitors, expiring in 2039, strengthening the ACX-375 pre-clinical antibiotic program.
Significant Reduction in Net Loss
Net loss decreased to $2.1 million from $4.4 million year-over-year, showing improved financial management despite ongoing R&D expenditures.
Publication Acceptance
Phase 2 clinical trial data accepted for publication in Lancet Microbe, showcasing ibezapolstat's high clinical cure rates and safety profile.